DOI . ORG {}

Analyzed Page
Matching Content Categories
CMS
Monthly Traffic Estimate
How Does Doi.org Make Money
Keywords
Topics
Questions
Schema
External Links
Analytics And Tracking
Libraries
Hosting Providers
CDN Services

We began analyzing https://link.springer.com/article/10.1007/s40265-024-01993-x, but it redirected us to https://link.springer.com/article/10.1007/s40265-024-01993-x. The analysis below is for the second page.

Title[redir]:
Adult-Onset Still’s Disease (AOSD): Advances in Understanding Pathophysiology, Genetics and Emerging Treatment Options | Drugs
Description:
Adult-onset Still’s disease (AOSD) is a multisystemic complex disorder clinically characterised by episodes of spiking fever, evanescent rash, polyarthritis or diffuse arthralgias; multiorgan involvement may develop according to the hyper-inflammatory extent. The pathogenesis of AOSD is not completely recognised. The central role of macrophage activation, which results in T helper 1 (Th1) cell cytokine activation, is well established. Pro-inflammatory cytokines such as interleukin (IL)-1, IL-6 and IL-18 play a fundamental role in disease onset and progression. The disease may develop in both children and adults with overlapping clinical features, and although several subsets depending on the clinical manifestations and the cytokines expressed have been identified, the dichotomy between systemic juvenile idiopathic arthritis (sJIA) and AOSD nowadays has been overcome, and the pathology is considered a disease continuum between ages. Various therapeutic approaches have been evaluated thus far, and different compounds are under assessment for AOSD treatment. Historically, glucocorticoids have been employed for treating systemic manifestations of Still’s disease, while conventional synthetic disease modifying anti-rheumatic drugs (csDMARDs) demonstrated efficacy in controlling the articular manifestations. Currently, biological (b) DMARDs are widely employed; IL-1 inhibitors such as anakinra and canakinumab have proven to have high efficacy and an excellent safety profile and the anti-IL-6 tocilizumab is approved for sJIA, with several trials and longitudinal studies confirming its efficacy and safety. Moreover, in the light of the ‘window of opportunity’, new evidence showed that the earlier these treatments are initiated, the sooner clinical inactivity can be achieved. Other treatment options are being considered since several molecules involved in the disease pathophysiology can be targeted through various mechanisms. This review will provide a broad overview of AOSD pathophysiology, insights into specific organ manifestations and the currently available treatments with the identification of potential therapeutic targets involved in AOSD pathogenesis will be outlined.

Matching Content Categories {📚}

Health & Fitness
Science
Education

Content Management System {📝}

What CMS is doi.org built with?

Custom-built

No common CMS systems were detected on Doi.org, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of doi.org audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 5,000,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Doi.org Make Money? {💸}

We don't see any clear sign of profit-making.

The purpose of some websites isn't monetary gain; they're meant to inform, educate, or foster collaboration. Everyone has unique reasons for building websites. This could be an example. Doi.org could be getting rich in stealth mode, or the way it's monetizing isn't detectable.

Keywords {🔍}

disease, pubmed, article, google, scholar, aosd, stills, patients, cas, adultonset, arthritis, treatment, central, systemic, efficacy, rheumatol, clinical, adult, levels, study, juvenile, safety, onset, httpsdoiorgs, rheum, idiopathic, manifestations, reported, nlrp, cells, activation, studies, ferritin, refractory, inhibitors, adults, syndrome, higher, activity, clin, dis, interleukin, sjia, observed, mas, receptor, ann, drugs, macrophage, therapeutic,

Topics {✒️}

granulocyte–macrophage colony-stimulating factor targets il-1β/il-1f2-induced signalling 2-ethoxy-5-oxo-tetrahydro-furan-3-yl diacerein downregulates nlrp3/caspase-1/il-1β disease-modifying anti-rheumatic drugs phase iiib/iv open-label colony-stimulating factor 1 andrea doria & paolo sfriso article download pdf nlrp3/caspase-1/il-1β axis aa/cc/tt haplotype de león-nava ma jak-i-related side effects catastrophic anti-phospholipid syndrome ifn-γ-producing th1 cells gm-csf-alpha receptor human monoclonal antibody real-world clinical setting tumour necrosis factor dramatic pro-inflammatory cascade long-term extension phase exert anti-inflammatory effects steroidal anti-inflammatory drugs potent anti-inflammatory effect phase ib/iia randomised central cytokine involved potent pro-inflammatory cytokine receptor-bound ifn-γ igg4 monoclonal antibody consistent steroid-sparing effect il-1r inhibitor anakinra juvenile idiopathic arthritis ifn-γ resulted increased il-4-producing th2 cells inflammasome-induced pyroptosis higher 18f-fdg uptake anti-il-1β/il-18 human receptor antagonist potential anti-inflammatory effect discriminate active adult-onset open-label trial reducing il-1β production gm-csf blockade migration inhibitory factor preventing il-1β release privacy choices/manage cookies label anti-interleukin-1 treatments bmc musculoskelet disord card8 gene encoding positron emission tomography

Questions {❓}

Adult-onset Still’s disease or systemic-onset juvenile idiopathic arthritis and spondyloarthritis: overlapping syndrome or phenotype shift?

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Adult-Onset Still’s Disease (AOSD): Advances in Understanding Pathophysiology, Genetics and Emerging Treatment Options
         description:Adult-onset Still’s disease (AOSD) is a multisystemic complex disorder clinically characterised by episodes of spiking fever, evanescent rash, polyarthritis or diffuse arthralgias; multiorgan involvement may develop according to the hyper-inflammatory extent. The pathogenesis of AOSD is not completely recognised. The central role of macrophage activation, which results in T helper 1 (Th1) cell cytokine activation, is well established. Pro-inflammatory cytokines such as interleukin (IL)-1, IL-6 and IL-18 play a fundamental role in disease onset and progression. The disease may develop in both children and adults with overlapping clinical features, and although several subsets depending on the clinical manifestations and the cytokines expressed have been identified, the dichotomy between systemic juvenile idiopathic arthritis (sJIA) and AOSD nowadays has been overcome, and the pathology is considered a disease continuum between ages. Various therapeutic approaches have been evaluated thus far, and different compounds are under assessment for AOSD treatment. Historically, glucocorticoids have been employed for treating systemic manifestations of Still’s disease, while conventional synthetic disease modifying anti-rheumatic drugs (csDMARDs) demonstrated efficacy in controlling the articular manifestations. Currently, biological (b) DMARDs are widely employed; IL-1 inhibitors such as anakinra and canakinumab have proven to have high efficacy and an excellent safety profile and the anti-IL-6 tocilizumab is approved for sJIA, with several trials and longitudinal studies confirming its efficacy and safety. Moreover, in the light of the ‘window of opportunity’, new evidence showed that the earlier these treatments are initiated, the sooner clinical inactivity can be achieved. Other treatment options are being considered since several molecules involved in the disease pathophysiology can be targeted through various mechanisms. This review will provide a broad overview of AOSD pathophysiology, insights into specific organ manifestations and the currently available treatments with the identification of potential therapeutic targets involved in AOSD pathogenesis will be outlined.
         datePublished:2024-03-05T00:00:00Z
         dateModified:2024-03-05T00:00:00Z
         pageStart:257
         pageEnd:274
         license:http://creativecommons.org/licenses/by-nc/4.0/
         sameAs:https://doi.org/10.1007/s40265-024-01993-x
         keywords:
            Pharmacotherapy
            Pharmacology/Toxicology
            Internal Medicine
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs40265-024-01993-x/MediaObjects/40265_2024_1993_Fig1_HTML.png
         isPartOf:
            name:Drugs
            issn:
               1179-1950
               0012-6667
            volumeNumber:84
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Springer International Publishing
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Sara Bindoli
               url:http://orcid.org/0000-0002-9409-3329
               affiliation:
                     name:University of Padova
                     address:
                        name:Rheumatology Unit, Department of Medicine, University of Padova, Padua, Italy
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Chiara Baggio
               url:http://orcid.org/0000-0002-3255-9314
               affiliation:
                     name:University of Padova
                     address:
                        name:Rheumatology Unit, Department of Medicine, University of Padova, Padua, Italy
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Andrea Doria
               url:http://orcid.org/0000-0003-0548-4983
               affiliation:
                     name:University of Padova
                     address:
                        name:Rheumatology Unit, Department of Medicine, University of Padova, Padua, Italy
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Paolo Sfriso
               url:http://orcid.org/0000-0001-6432-7174
               affiliation:
                     name:University of Padova
                     address:
                        name:Rheumatology Unit, Department of Medicine, University of Padova, Padua, Italy
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
         isAccessibleForFree:1
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Adult-Onset Still’s Disease (AOSD): Advances in Understanding Pathophysiology, Genetics and Emerging Treatment Options
      description:Adult-onset Still’s disease (AOSD) is a multisystemic complex disorder clinically characterised by episodes of spiking fever, evanescent rash, polyarthritis or diffuse arthralgias; multiorgan involvement may develop according to the hyper-inflammatory extent. The pathogenesis of AOSD is not completely recognised. The central role of macrophage activation, which results in T helper 1 (Th1) cell cytokine activation, is well established. Pro-inflammatory cytokines such as interleukin (IL)-1, IL-6 and IL-18 play a fundamental role in disease onset and progression. The disease may develop in both children and adults with overlapping clinical features, and although several subsets depending on the clinical manifestations and the cytokines expressed have been identified, the dichotomy between systemic juvenile idiopathic arthritis (sJIA) and AOSD nowadays has been overcome, and the pathology is considered a disease continuum between ages. Various therapeutic approaches have been evaluated thus far, and different compounds are under assessment for AOSD treatment. Historically, glucocorticoids have been employed for treating systemic manifestations of Still’s disease, while conventional synthetic disease modifying anti-rheumatic drugs (csDMARDs) demonstrated efficacy in controlling the articular manifestations. Currently, biological (b) DMARDs are widely employed; IL-1 inhibitors such as anakinra and canakinumab have proven to have high efficacy and an excellent safety profile and the anti-IL-6 tocilizumab is approved for sJIA, with several trials and longitudinal studies confirming its efficacy and safety. Moreover, in the light of the ‘window of opportunity’, new evidence showed that the earlier these treatments are initiated, the sooner clinical inactivity can be achieved. Other treatment options are being considered since several molecules involved in the disease pathophysiology can be targeted through various mechanisms. This review will provide a broad overview of AOSD pathophysiology, insights into specific organ manifestations and the currently available treatments with the identification of potential therapeutic targets involved in AOSD pathogenesis will be outlined.
      datePublished:2024-03-05T00:00:00Z
      dateModified:2024-03-05T00:00:00Z
      pageStart:257
      pageEnd:274
      license:http://creativecommons.org/licenses/by-nc/4.0/
      sameAs:https://doi.org/10.1007/s40265-024-01993-x
      keywords:
         Pharmacotherapy
         Pharmacology/Toxicology
         Internal Medicine
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs40265-024-01993-x/MediaObjects/40265_2024_1993_Fig1_HTML.png
      isPartOf:
         name:Drugs
         issn:
            1179-1950
            0012-6667
         volumeNumber:84
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Springer International Publishing
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Sara Bindoli
            url:http://orcid.org/0000-0002-9409-3329
            affiliation:
                  name:University of Padova
                  address:
                     name:Rheumatology Unit, Department of Medicine, University of Padova, Padua, Italy
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Chiara Baggio
            url:http://orcid.org/0000-0002-3255-9314
            affiliation:
                  name:University of Padova
                  address:
                     name:Rheumatology Unit, Department of Medicine, University of Padova, Padua, Italy
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Andrea Doria
            url:http://orcid.org/0000-0003-0548-4983
            affiliation:
                  name:University of Padova
                  address:
                     name:Rheumatology Unit, Department of Medicine, University of Padova, Padua, Italy
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Paolo Sfriso
            url:http://orcid.org/0000-0001-6432-7174
            affiliation:
                  name:University of Padova
                  address:
                     name:Rheumatology Unit, Department of Medicine, University of Padova, Padua, Italy
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
      isAccessibleForFree:1
["Periodical","PublicationVolume"]:
      name:Drugs
      issn:
         1179-1950
         0012-6667
      volumeNumber:84
Organization:
      name:Springer International Publishing
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:University of Padova
      address:
         name:Rheumatology Unit, Department of Medicine, University of Padova, Padua, Italy
         type:PostalAddress
      name:University of Padova
      address:
         name:Rheumatology Unit, Department of Medicine, University of Padova, Padua, Italy
         type:PostalAddress
      name:University of Padova
      address:
         name:Rheumatology Unit, Department of Medicine, University of Padova, Padua, Italy
         type:PostalAddress
      name:University of Padova
      address:
         name:Rheumatology Unit, Department of Medicine, University of Padova, Padua, Italy
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Sara Bindoli
      url:http://orcid.org/0000-0002-9409-3329
      affiliation:
            name:University of Padova
            address:
               name:Rheumatology Unit, Department of Medicine, University of Padova, Padua, Italy
               type:PostalAddress
            type:Organization
      name:Chiara Baggio
      url:http://orcid.org/0000-0002-3255-9314
      affiliation:
            name:University of Padova
            address:
               name:Rheumatology Unit, Department of Medicine, University of Padova, Padua, Italy
               type:PostalAddress
            type:Organization
      name:Andrea Doria
      url:http://orcid.org/0000-0003-0548-4983
      affiliation:
            name:University of Padova
            address:
               name:Rheumatology Unit, Department of Medicine, University of Padova, Padua, Italy
               type:PostalAddress
            type:Organization
      name:Paolo Sfriso
      url:http://orcid.org/0000-0001-6432-7174
      affiliation:
            name:University of Padova
            address:
               name:Rheumatology Unit, Department of Medicine, University of Padova, Padua, Italy
               type:PostalAddress
            type:Organization
      email:[email protected]
PostalAddress:
      name:Rheumatology Unit, Department of Medicine, University of Padova, Padua, Italy
      name:Rheumatology Unit, Department of Medicine, University of Padova, Padua, Italy
      name:Rheumatology Unit, Department of Medicine, University of Padova, Padua, Italy
      name:Rheumatology Unit, Department of Medicine, University of Padova, Padua, Italy

External Links {🔗}(679)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Prism.js

Emails and Hosting {✉️}

Mail Servers:

mx.zoho.eu
mx2.zoho.eu
mx3.zoho.eu

Name Servers:

josh.ns.cloudflare.com
zita.ns.cloudflare.com

CDN Services {📦}

Crossref

5.29s.